Advantages and disadvantages of using intravenous tissue Plasminogen activator as salvage therapy for inoperable HeartWare thrombosis

Robyn Basken, Charles M. Bazzell, Richard Smith, Rajesh Janardhanan, Zain Khalpey

Research output: Research - peer-reviewArticle

Abstract

Device thrombosis is a devastating complication of left ventricular assist devices. The definitive treatment has been device exchange or explant. Evidence of increasing morbidity and mortality with device exchange has shifted strategies toward conservative management. In this report, we detail the use of thrombolytics as salvage therapy in a patient with an occlusive HeartWare ventricular assist device (HeartWare Inc., Framingham, MA) thrombus, resulting in long-term survival without further intervention.

LanguageEnglish (US)
Pages443-446
Number of pages4
JournalJournal of Cardiac Surgery
Volume32
Issue number7
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Salvage Therapy
Tissue Plasminogen Activator
Thrombosis
Equipment and Supplies
Heart-Assist Devices
Morbidity
Survival
Mortality
Therapeutics
Conservative Treatment

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Advantages and disadvantages of using intravenous tissue Plasminogen activator as salvage therapy for inoperable HeartWare thrombosis. / Basken, Robyn; Bazzell, Charles M.; Smith, Richard; Janardhanan, Rajesh; Khalpey, Zain.

In: Journal of Cardiac Surgery, Vol. 32, No. 7, 01.07.2017, p. 443-446.

Research output: Research - peer-reviewArticle

Basken, Robyn ; Bazzell, Charles M. ; Smith, Richard ; Janardhanan, Rajesh ; Khalpey, Zain. / Advantages and disadvantages of using intravenous tissue Plasminogen activator as salvage therapy for inoperable HeartWare thrombosis. In: Journal of Cardiac Surgery. 2017 ; Vol. 32, No. 7. pp. 443-446
@article{508dfa7a67ab42f38ab179779a0b31d6,
title = "Advantages and disadvantages of using intravenous tissue Plasminogen activator as salvage therapy for inoperable HeartWare thrombosis",
abstract = "Device thrombosis is a devastating complication of left ventricular assist devices. The definitive treatment has been device exchange or explant. Evidence of increasing morbidity and mortality with device exchange has shifted strategies toward conservative management. In this report, we detail the use of thrombolytics as salvage therapy in a patient with an occlusive HeartWare ventricular assist device (HeartWare Inc., Framingham, MA) thrombus, resulting in long-term survival without further intervention.",
author = "Robyn Basken and Bazzell, {Charles M.} and Richard Smith and Rajesh Janardhanan and Zain Khalpey",
year = "2017",
month = "7",
doi = "10.1111/jocs.13165",
volume = "32",
pages = "443--446",
journal = "Journal of Cardiac Surgery",
issn = "0886-0440",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Advantages and disadvantages of using intravenous tissue Plasminogen activator as salvage therapy for inoperable HeartWare thrombosis

AU - Basken,Robyn

AU - Bazzell,Charles M.

AU - Smith,Richard

AU - Janardhanan,Rajesh

AU - Khalpey,Zain

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Device thrombosis is a devastating complication of left ventricular assist devices. The definitive treatment has been device exchange or explant. Evidence of increasing morbidity and mortality with device exchange has shifted strategies toward conservative management. In this report, we detail the use of thrombolytics as salvage therapy in a patient with an occlusive HeartWare ventricular assist device (HeartWare Inc., Framingham, MA) thrombus, resulting in long-term survival without further intervention.

AB - Device thrombosis is a devastating complication of left ventricular assist devices. The definitive treatment has been device exchange or explant. Evidence of increasing morbidity and mortality with device exchange has shifted strategies toward conservative management. In this report, we detail the use of thrombolytics as salvage therapy in a patient with an occlusive HeartWare ventricular assist device (HeartWare Inc., Framingham, MA) thrombus, resulting in long-term survival without further intervention.

UR - http://www.scopus.com/inward/record.url?scp=85021293338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021293338&partnerID=8YFLogxK

U2 - 10.1111/jocs.13165

DO - 10.1111/jocs.13165

M3 - Article

VL - 32

SP - 443

EP - 446

JO - Journal of Cardiac Surgery

T2 - Journal of Cardiac Surgery

JF - Journal of Cardiac Surgery

SN - 0886-0440

IS - 7

ER -